Valeant Pharmaceuticals (NYSE:VRX) issued an update on its FY14 earnings guidance on Tuesday morning. The company provided EPS guidance of $8.25-8.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.71, Analyst RN reports. The company issued revenue guidance of $8.2-8.6 billion, compared to the consensus revenue estimate of $8.16 billion.Valeant Pharmaceuticals […]
Valeant Pharmaceuticals (VRX) Releases FY14 Earnings Guidance is a post from: Zolmax
The post Valeant Pharmaceuticals (VRX) Releases FY14 Earnings Guidance appeared first on Zolmax.